Tradestie Institutional Equity Comparison Engine

ICCC vs OBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ICCC
ICCC N/M vs OBIO N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin 15.2% vs -195.4% ยท YoY +11.5% vs -89.4%
Momentum & Technical Winner OBIO
1Y +88.8% vs +70.3% ยท 52W Pos 91% vs 92%
Options & Structure Winner OBIO
UNCLASSIFIED (N/A IV) vs BREAKOUT (<1st %ile IV)
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.12
-1.79% 1D
Market Cap $570.6M
1M Return +30.64%
1Y Return +70.33%
Forward P/E N/M
Unified AI Score
37.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 55.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICCC +88.76% OBIO +70.33% Spread: +18.43 pp (ICCC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ICCC Revenue OBIO Revenue ICCC Op. Margin OBIO Op. Margin Margin Edge
FY2018 $10M N/A -13.2% N/A ICCC
FY2019 $10M N/A -7.0% N/A ICCC
FY2020 $20M N/A -9.0% N/A ICCC
FY2021 $20M N/A 1.3% N/A ICCC
FY2022 $20M $0M -12.4% -924.3% ICCC
FY2023 $20M $0M -32.9% -1866.2% ICCC
FY2024 $30M $0M -6.2% -2437.5% ICCC
FY2025 $30M $30M 6.0% -154.7% ICCC

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICCC (7) vs OBIO (2)
Institutional Metric ICCC OBIO Criterion Row Winner
Market Capitalization Scale $97.7M $570.6M Larger Scale OBIO
Trailing P/E Ratio Valuation 56.6x N/M Lower Multiple ICCC
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +11.5% -89.4% Higher Growth ICCC
Operating Margin (TTM) Profitability 15.2% -195.4% Higher Margin ICCC
Net Profit Margin Profitability 2.6% -182.5% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency 2.6% -182.3% Higher ROE ICCC
52-Week Range Position Momentum 91% ($5โ€“$12) 92% ($3โ€“$7) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 0.24ฮฒ ยท 46% Vol 1.15ฮฒ ยท 82% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 37.5 / 100 (SELL) Higher Composite ICCC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICCC vs OBIO Buy Guide
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
32d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICCC nor OBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.